At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 36 enrolled
Drug / intervention
Bivalent mRNA SARS-CoV-2 vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity to SARS-CoV-2 of Co-administering Bivalent mRNA BNT162b2 Booster and Quadrivalent Influenza Vaccine Among Healthy Volunteers: A Pilot Study
In Brief
A Early Phase 1 clinical trial evaluating Bivalent mRNA SARS-CoV-2 vaccine and Quardrivalent influenza vaccine for COVID - 19. Completed, enrolled 36 participants across 1 site.
Detailed Summary
This study, a pilot randomized controlled trial, single-blind (outcome assessor), evaluating the immune response (both humoral and cell-mediated) against SARS-CoV-2 and the safety of three different vaccine administration approaches: the SARS-CoV-2 mRNA vaccine alone, the influenza vaccine alone, and the co-administration of both vaccines.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID - 19
CountriesThailand
Collaborators--
Timeline
Early Ph 1CompletedFinished
20252026
Enrollment StartMar 2024
Primary CompletionMay 2024
First PostedFeb 2025
TodayJul 2026
First PostedFeb 18, 2025
Enrollment StartMar 1, 2024
Primary CompletionMay 31, 2024
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 1.4 years ago
Interventions
Bivalent mRNA SARS-CoV-2 vaccinebiological
Administering a booster dose of the bivalent mRNA vaccine BNT162b2
Quardrivalent influenza vaccinebiological
Administering a VaxigripTetra™